How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,006 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. Full Text available with Trip Pro

Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. House dust mite (HDM) respiratory allergy is a common and burdensome disease in children and adolescents. There are few HDM allergy immunotherapy trials in children with perennial allergic rhinitis. This post hoc analysis used pooled data to evaluate efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in adolescents (12-17 years).In two double-blind, placebo-controlled

2017 Pediatric Allergy and Immunology Controlled trial quality: predicted high

102. Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study. Full Text available with Trip Pro

Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study. Food allergies are increasing in prevalence but no treatment strategies are currently available to cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy (FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not been investigated in dogs. Therefore

2017 BMC veterinary research Controlled trial quality: uncertain

103. Hot Topics in Primary Care: Sublingual Immunotherapy: A Guide for Primary Care. (Abstract)

Hot Topics in Primary Care: Sublingual Immunotherapy: A Guide for Primary Care. Allergen immunotherapy (AIT), the only potential disease-modifying treatment for allergic disease, has been used for more than a century. Hankin et al showed significant reduction in pharmacy, outpatient, and inpatient resources in the 6 months following vs the 6 months preceding AIT in Medicaid-enrolled children with allergic rhinitis (AR). A 2013 analysis showed sustained cost reduction over 18 months in patients

2017 Journal of Family Practice

104. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Full Text available with Trip Pro

Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term efficacy. However, there are few real-life data on the progression of AR and/or AA in patients receiving AIT.To assess the real-world, long-term efficacy of grass pollen sublingual immunotherapy (SLIT) tablets in AR

2017 Allergy

105. [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma]

[Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] S Shin, HJ Song, SY Park, YJ Jung, JY Park, J Ahn, YM Yea Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation S Shin, HJ Song, SY Park, YJ Jung, JY Park, J Ahn, YM Yea. [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-11-006. 2011 Authors' conclusions Disease burdens of allergic rhinitis and asthma have recently been

2011 Health Technology Assessment (HTA) Database.

106. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy-related asthma.To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period.Double-blind, randomized, placebo-controlled trial conducted

2016 JAMA Controlled trial quality: predicted high

107. Sublingual Immunotherapy

Sublingual Immunotherapy Sublingual Immunotherapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sublingual Immunotherapy Sublingual (...) Immunotherapy Aka: Sublingual Immunotherapy , Grastek , Oralair , Ragwitek From Related Chapters II. Indications Allergy For allergic symptoms refractory to standard allergy medications III. Precautions Not to be used without formal ing first Observe in office for first sublingual dose All patients should receive auto-injector in case of reaction IV. Preparations Grass allergies Grastek Oralair Ragweed allergy Ragwitek V. Dosing: Protocol Start medication 3-4 months prior to allergy season and continue

2018 FP Notebook

108. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. (Abstract)

Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Recently, a series of assays has been conducted in which sublingual immunotherapy (SLIT) maintenance extracts of European manufacturers were compared with U.S. concentrated extracts by using U.S. Food and Drug Administration recommended in vitro testing. These test results have been published. We herein performed further data analysis to facilitate (...) interpretation of SLIT dosing by U.S. physicians.To express the allergen quantity of maintenance SLIT as recommended by European manufacturers relative to U.S. subcutaneous immunotherapy (SCIT) maintenance dosing.We analyzed the maintenance SLIT solutions of Dermatophagoides pteronyssinus, timothy grass pollen, cat, and ragweed pollen from four European manufacturers and concentrated extracts from three U.S. manufacturers and from the U.S. Food and Drug Administration. Here, we expressed the potency

2016 Allergy and Asthma Proceedings

109. [Efficacy of sublingual immunotherapy and subcutaneous immunotherapy in children with allergic rhinitis]. (Abstract)

[Efficacy of sublingual immunotherapy and subcutaneous immunotherapy in children with allergic rhinitis]. Objective:To evaluate the efficacy and safety of sublingual immunotherapy(SLIT) and subcutaneous immunotherapy(SCIT) in children with pediatric allergic rhinitis.Method:This study retrospectively analyzed the efficacy and safety of SLIT and SCIT in 186 children with allergic rhinitis which induced by house dust mites.Patients were randomly divided into two groups:SLIT group consisted of 104

2016 Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery Controlled trial quality: uncertain

110. Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study Full Text available with Trip Pro

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study The majority of allergic patients are poly-sensitized. For causal treatment by allergy immunotherapy (AIT) a single or few allergen products containing the clinically most relevant allergens are applied, but few data on tolerability of multiple application of AIT is available. The aim of our study was to investigate safety (...) and tolerability in patients who started treatment by sublingual immunotherapy (SLIT) with the standardised SQ(®) grass SLIT-tablet and were treated with concomitant AIT products.In a non-interventional, open-label, observational study in Germany treatment of patients with the SQ(®) grass SLIT-tablet and concomitant AIT (SCIT or SLIT) was documented between January 2012 and January 2014. Patients were followed at visits at first administration of the SQ(®) grass SLIT-tablet and after 1-3 months of treatment

2016 Clinical and translational allergy

111. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. (Abstract)

factors for SRs: a history of SRs to SCIT, the administration of injections in patients with uncontrolled asthma, use of accelerated buildup regimens, and never adjusting doses during the height of the allergy season. Delayed-onset SRs beginning >30 minutes after injections represented 15% of all SRs in clinics with 30-minute observation periods. The safety profile of sublingual immunotherapy is favorable, with no FRs yet identified for sublingual tablet or liquid formulations. Risk management should (...) Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. In 2004, it was estimated that one fatal anaphylactic reaction (FR) occurred in every 2.4 million subcutaneous immunotherapy (SCIT) injection visits. Uncontrolled asthma was the most commonly cited factor that contributed to FRs. Results of the annual American College of Allergy, Asthma, and Immunology/American Academy

2020 Allergy and Asthma Proceedings

112. Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. (Abstract)

Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. Patient compliance is critical for successful allergen immunotherapy (AIT). Previous studies suggest that AIT compliance is worse outside of controlled clinical trials, with reported subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) noncompliance at 11% to 50% and 3% to 25%, respectively.A retrospective review of 384 AIT patients at a single, tertiary care otolaryngic allergy practice

2015 International forum of allergy & rhinology

113. Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). (Abstract)

Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). Allergy immunotherapy has been used to help alleviate symptoms of allergic diseases for over 100 years. In the setting of the recently approved sublingual immunotherapy, allergists are now faced with which therapeutic regimen to use in clinical practice, sublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT). Both SLIT and SCIT have been shown to be beneficial for the therapy (...) of seasonal allergic rhinoconjunctivitis. Each therapeutic measure has its associated benefits. SLIT has a better safety profile with less systemic reactions and to date, no reported fatal reactions. SCIT, the primary method of allergen immunotherapy in the United States, has a slightly better efficacy profile and readily allows for treatment of polyallergic patients. This review focuses on how to incorporate SLIT into daily clinical practice and on how to choose SLIT versus SCIT.

2015 Allergy and Asthma Proceedings

114. Sublingual immunotherapy for allergic rhinitis

Sublingual immunotherapy for allergic rhinitis Sublingual immunotherapy for allergic rhinitis Sublingual immunotherapy for allergic rhinitis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sublingual immunotherapy for allergic rhinitis. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' conclusions Sublingual immunotherapy involves the administration (...) of a diluted dose of an allergen under the tongue, which allows the material to contact the oral mucosa. Sublingual immunotherapy has been investigated in patients with allergic rhinitis and/or asthma associated with sensitivity to seasonal allergens, and to allergens such as dust mites, mold, pet dander, or nuts. In contrast to standard immunotherapy, which requires subcutaneous injections, sublingual therapy may offer a lower risk of serious side effects, and may be more comfortable and acceptable

2011 Health Technology Assessment (HTA) Database.

115. ASCIA Guide - Aeroallergen Immunotherapy

farinae OAS Oral allergy syndrome DP Dermatophagoides pteronyssinus QOL Quality of life FDA Food and Drug Administration (USA) RCT Randomised controlled trials GMP Good manufacturing practice sIgE Allergen specific IgE HDM House dust mite SCIT Subcutaneous immunotherapy HSA Human Serum Albumin SLIT Sublingual immunotherapy IgE Immunoglobulin E SOTI Specific oral tolerance induction IgG Immunoglobulin G SPT Skin prick test IDT Intradermal test SR Systemic reactions IT Immunotherapy TGA Therapeutic (...) ASCIA Guide - Aeroallergen Immunotherapy Aeroallergen Immunotherapy A Guide for Clinical Immunology/Allergy Specialists This document supersedes information contained in the 2015 ASCIA Allergen Immunotherapy Manual. It has been updated by the ASCIA Immunotherapy Working Party and extracted into this separate Guide. ASCIA Immunotherapy Working Party members are listed on the ASCIA website www.allergy.org.au/members/committees#wpim ASCIA resources are based on published literature and expert

2019 Australasian Society of Clinical Immunology and Allergy

116. Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study Full Text available with Trip Pro

in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products.In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment. Adverse events (AEs) were recorded by the physicians and by patients in diaries, and coded using the Medical Dictionary for Regulatory Activities (MedDRA).Three hundred and seven patients were treated (...) Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available.The aim of our study was to investigate safety and tolerability

2017 Drugs - real world outcomes

117. Role of Immunotherapy in the Treatment of Asthma

. It may also improve quality of life and FEV1, (a measure of the ability to exhale) and reduce the use of quick-relief medications (short-acting bronchodilators) and systemic corticosteroids. • Sublingual immunotherapy improves asthma symptoms, quality of life and FEV 1, and reduces the use of long-term control medications. It may also reduce the use of quick- relief medications. • Local and systemic reactions to subcutaneous immunotherapy and sublingual immunotherapy are common but infrequently (...) . To evaluate the efficacy and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in the treatment of allergic asthma. Data Sources. We searched PubMed, Embase, and CENTRAL through May 8, 2017. Methods. Two reviewers independently selected randomized controlled trials (RCTs) of the efficacy of SCIT and SLIT and RCTs, observational studies, and case series or case reports on safety. Two reviewers independently assessed the risk of bias for each study and together graded

2018 Effective Health Care Program (AHRQ)

118. Sublingual Omp16-driven redirection of the allergic intestinal response in a pre-clinical model of food allergy. (Abstract)

Sublingual Omp16-driven redirection of the allergic intestinal response in a pre-clinical model of food allergy. IgE-mediated food allergy remains a significant and growing worldwide problem. Sublingual immunotherapy (SLIT) shows an excellent safety profile for food allergy, but the clinical efficacy needs to be improved. This study assessed the effects of the Toll-like receptor 4 agonist outer membrane protein (Omp) 16 from Brucella abortus combined with cow´s milk proteins (CMP) through (...) the sublingual route to modulate cow's milk allergy in an experimental model.Mice sensitized with cholera toxin and CMP were orally challenged with the allergen to elicit hypersensitivity reactions. Then, mice were treated with a very low amount of CMP along with Omp16 as a mucosal adjuvant, and finally, animals were re-exposed to CMP. Systemic and mucosal immune parameters were assessed in vivo and in vitro.We found that the sublingual administration of Omp16 + CMP induced a buccal Th1 immune response

2020 Clinical and Experimental Allergy

119. The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day. Full Text available with Trip Pro

The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day. Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR). However, many issues regarding SLIT remain to be resolved, including the optimal timing of administration. This study investigated the effect of time of day on SLIT efficacy with the goal of optimizing the therapeutic outcome.We performed prophylactic SLIT at different times of day (10 a.m. or 10 p.m.) in 2 (...) mouse models of AR: an ovalbumin (OVA)-induced AR model and Cry j 1-induced AR model, and compared the effects.In the OVA-induced AR model, mice sublingually receiving OVA at 10 a.m. exhibited a greater decrease in total and OVA-specific IgE levels than mice treated at 10 p.m. In addition, mice treated at 10 a.m. exhibited reductions in OVA-specific IL-4, IL-10, and IL-13 production by splenocytes relative to mice treated at 10 p.m. Furthermore, we observed a more efficient capture of sublingually

2016 International Archives of Allergy and Immunology

120. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. (Abstract)

Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Treatment with SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is effective for HDM respiratory allergic disease, but data on long-term effects are lacking.Post hoc analyses were conducted to determine the long-term effect of SQ HDM SLIT-tablet on nasal, ocular, and cough symptoms 1 year after discontinuation of treatment.Study participants underwent environmental

2016 Asthma & Immunology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>